April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Risk Factors for Development of Zone I versus Zone II Retinopathy of Prematurity: A Retrospective Analysis of the Early Treatment of Retinopathy of Prematurity Study (ET-ROP)
Author Affiliations & Notes
  • Mynna Ishikiriyama
    Ophthalmology, University of California-San Francisco, San Francisco, CA
    Ophthalmology, Santa Casa of Sao Paulo, Sao Paulo, Brazil
  • Ashleigh Levison
    Ophthalmology, University of California-San Francisco, San Francisco, CA
    Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
  • Michael Deiner
    Ophthalmology, University of California-San Francisco, San Francisco, CA
  • Alejandra G de Alba Campomanes
    Ophthalmology, University of California-San Francisco, San Francisco, CA
  • Footnotes
    Commercial Relationships Mynna Ishikiriyama, None; Ashleigh Levison, None; Michael Deiner, None; Alejandra de Alba Campomanes, Bayer (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5909. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mynna Ishikiriyama, Ashleigh Levison, Michael Deiner, Alejandra G de Alba Campomanes; Risk Factors for Development of Zone I versus Zone II Retinopathy of Prematurity: A Retrospective Analysis of the Early Treatment of Retinopathy of Prematurity Study (ET-ROP). Invest. Ophthalmol. Vis. Sci. 2014;55(13):5909.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine baseline characteristics associated with risk for development of Zone I versus Zone II retinopathy of prematurity (ROP)

Methods: ET-ROP data was obtained as an MS Access database which we decoded and transferred into Stata for analysis. Of the 401 patients randomized, 317 with bilateral disease had one eye randomized to early treatment, and 44 patients with asymmetric disease were randomized to early treatment. Of these 361 patients, we identified infants with Zone I versus Zone II disease. We defined an infant as having Zone I disease if they had any stage 2 or 3 in Zone I. We included stage 1 disease if they had no worse disease in Zone II. An infant with Zone II disease was defined as an infant who did not meet criteria for Zone I disease but had any stage, 1,2, or 3 in Zone II. Risk factors analyzed included birth weight (BW), gestational age (GA), sex, race, singleton vs. multiple birth, congenital anomalies, and inborn vs. transfer using univariate and multivariate analysis.

Results: The mean GA and BW for infants with Zone I disease was 24.7 weeks and 665.6g and for those with Zone II disease was 25.4 weeks and 724.8g. (p value=0.0008 and 0.0001, respectively). In the initial multivariate analysis GA, BW and African American race were found to be statistically significant risk factors for the development of Zone I ROP. For every 100 g decrease in BW, the risk of developing Zone I disease increased by 30% (OR 1.30, 95% 1.10-1.54). African Americans (n=64) had a significantly higher risk of developing Zone I ROP (OR=3.78, CI 2.06-6.96, p<0.001) compared to Caucasian patients (n=230) when controlling for all other variables.

Conclusions: In the ET-ROP study, BW was a significant risk factor for the development of Zone I ROP. Data from CRYO-ROP suggested African American patients are less likely to develop severe ROP. This re-analysis of ET-ROP suggests that African Americans have a higher risk of developing Zone I ROP than Zone II ROP. when controlling for birth weight and other baseline characteristics.

Keywords: 706 retinopathy of prematurity • 464 clinical (human) or epidemiologic studies: risk factor assessment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×